Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology
163,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
82 °P sammeln
  • Broschiertes Buch

Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors,…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more.

Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications-arrhythmias, heart failure, and even death.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. Imteyaz Qamar is working as an assistant professor at School of biotechnology, Gautam Buddha University, Greater Noida, India. His area on interest is Stress biology, and Cancer Genetics

He earned his Ph.D. in Molecular Endocrinology from Chonnam National University, South Korea with an emphasis on gene regulation and physiological function of an androgen receptor corepressor-19kD using mice model. He has written various manuscripts, grants, progress reports, pre-IND protocols, animal protocols and published in well reputed international journals. He has also received various awards such as Brain Korea-21 Best Research presenter award 2007, Bharath Vikas award 2016, Young Scientist Award 2017 & 2019, STE meritorious award 2019 etc. He serves as a member of editorial boards of various peer reviewed journals. He is also a member of the endocrinology society, United States of America (USA).
Rezensionen
"...a multi-authored reference text on cardiovascular toxicity and therapeutic modalities targeting cardio-oncology [by] national and international thought leaders in their respective fields . This book gives a comprehensive, up-to-date overview of the basics of the cardiovascular system, cardiovascular diseases in cancer survivors, recent trends in cancer immunotherapy, cardiotoxic effects of various chemo- radiotherapeutic modalities, and biomarkers involved in such cardiotoxicities [with] an overview of topics such as hemopoietic stem cell transplant, stroke risk in cancer patients, cardiovascular imaging, and cardiac rehabilitation . This book is a valuable resource The authors have done the utmost justice in providing high-quality content." --©Doody s Review Service, 2023, Aditya Nitin Thakkar, MD (East Tennessee State University Quillen College of Medicine)